{
  "meta": {
    "timestamp": "2025-01-06T14:20:15.102992",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "IDEAYA Biosciences Inc.",
      "symbol": "IDYA",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Clinical trial risks including potential failures, delays, or unfavorable results",
            "Regulatory hurdles that could delay or prevent market approval",
            "Financial sustainability concerns due to reliance on external funding",
            "High market competition in the oncology space",
            "Dependency on strategic partnerships with companies like Gilead Sciences and Amgen"
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Commitment to developing precision medicines for cancer patients, focusing on reducing treatment side effects and improving patient outcomes"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "IDEAYA Biosciences",
              "snippet": "IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors December 29, 2024 December 27, 2024",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554786+00:00",
              "published_date": null,
              "source_hash": "75ce7991b38187448001a8ff708bdc14"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "IDEAYA Biosciences, Inc. (the \"Company\") and involve knownand unknown risks, uncertainties and other factorsthat may cause the actual results, levels of activity,performance or achievementsof the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554896+00:00",
              "published_date": null,
              "source_hash": "477155083f625065e6338f5817c4b2be"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Aug. 6, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update, and announced financial results for the second quarter ended June 30, 2024.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554910+00:00",
              "published_date": null,
              "source_hash": "6c6c3069fb83fa8d61a0884ac1db67ab"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 ...",
              "snippet": "IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554922+00:00",
              "published_date": null,
              "source_hash": "d6c9bf5e85d39b3379a36fcbccb98906"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces IND-Clearance for Werner Helicase ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Oct. 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592250+00:00",
              "published_date": null,
              "source_hash": "ed08ea56824dd8db74c7bc73f40911ac"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress",
              "snippet": "In its third-quarter 2024 earnings report, IDEAYA Biosciences highlighted significant advancements in its clinical trials, including progress with darovasertib and IDE397, alongside a substantial ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554945+00:00",
              "published_date": null,
              "source_hash": "904fdfc2576ead6307c4841024c828b0"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines September 2023. Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the ... Pursuant to Amgen Clinical Trial Collaboration and Supply Agreement for IDE397 + AMG 193 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554954+00:00",
              "published_date": null,
              "source_hash": "af47ea542300a9889e6f91f9bd30982e"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines October 2022. Certain statements in this presentation and the accompanying oral commentary are forwardlooking statements. These statements re- late to future events ... Pursuant to Amgen Clinical Trial Collaboration and Supply Agreement for IDE397 + AMG 193, an ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554963+00:00",
              "published_date": null,
              "source_hash": "649e92c63d1a8291d589cb0b50404c62"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. (IDYA) Company Profile & Overview - Stock Analysis",
              "snippet": "Company profile for IDEAYA Biosciences, Inc. (IDYA) with a description, list of executives, contact details and other key facts. ... IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554972+00:00",
              "published_date": null,
              "source_hash": "a6ceb7580de58cbb1edc3705f88ad21a"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. Company Profile - Dun & Bradstreet",
              "snippet": "Find company research, competitor information, contact details & financial data for IDEAYA Biosciences, Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:45.554982+00:00",
              "published_date": null,
              "source_hash": "1446b3a92c56011fe8abf0b81404a0cd"
            },
            {
              "url": "",
              "title": "Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know",
              "snippet": "IDEAYA Biosciences, Inc. (IDYA) closed the last trading session at $30.41, gaining 3.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:48.211040+00:00",
              "published_date": "2024-11-08T05:55:00+00:00",
              "source_hash": "e40465195aa8c4a6277878059568f273"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma",
              "snippet": "SHR-4849's early clinical signals have been promising, showing tumor regression in preclinical studies and initial positive responses in small cell lung cancer subjects during the Phase 1 clinical trial ... 2024. IDEAYA Biosciences, Inc, a synthetic ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:48.211117+00:00",
              "published_date": "2025-01-01T07:13:00+00:00",
              "source_hash": "40d4bed25ccc991993a8a78bb3b40075"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor",
              "snippet": "Dec. 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:19:48.211131+00:00",
              "published_date": "2024-12-09T06:00:00+00:00",
              "source_hash": "80b585c5e74b9559693b571b72368c0c"
            },
            {
              "url": "",
              "title": "BeiGene, Brii and Ideaya ring in 2025 with deal news, betting billions in biobucks on prospects",
              "snippet": "Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:54.125636+00:00",
              "published_date": "2025-01-02T08:30:00+00:00",
              "source_hash": "7eaa182288dda36c7095646417fdcabb"
            },
            {
              "url": "",
              "title": "IDEAYA Signs License Agreement For ADC SHR-4849 With Jiangsu Hengrui Pharma",
              "snippet": "IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, Sunday announced that it has entered into an exclusive global",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:54.125645+00:00",
              "published_date": "2024-12-30T09:39:00+00:00",
              "source_hash": "c655b90d81dfe2283a13d56d7deed995"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces Development Candidate Nomination of IDE892 ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592131+00:00",
              "published_date": null,
              "source_hash": "af47ed510fdce5b7640b6365c805ed07"
            },
            {
              "url": "",
              "title": "2024-12-29 | IDEAYA Biosciences Enters Exclusive License ... - Stockhouse",
              "snippet": "SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592234+00:00",
              "published_date": null,
              "source_hash": "820a299b926b1ce043a33c3c5d26d20a"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Enters Exclusive License with Hengrui ... - BioSpace",
              "snippet": "Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592260+00:00",
              "published_date": null,
              "source_hash": "3746595cac0042eb2ce91849148f0a00"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces Development Candidate Nomination of IDE892 ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: ... the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592269+00:00",
              "published_date": null,
              "source_hash": "0e8dfc5007880dddb117d5774b73640a"
            },
            {
              "url": "",
              "title": "Ideaya enters license agreement for SHR-4849 with Jiangsu Hengrui",
              "snippet": "Ideaya Biosciences announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals. Under the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592278+00:00",
              "published_date": null,
              "source_hash": "2bb1f8158682e8af8ea3a8c78ed97f35"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 ...",
              "snippet": "Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592286+00:00",
              "published_date": null,
              "source_hash": "f2c42750e87a60b3430e9d39ac9106c2"
            },
            {
              "url": "",
              "title": "IDEAYA Announces Webcast to Report Interim Phase 2 Data for ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592296+00:00",
              "published_date": null,
              "source_hash": "3add3f75095fadeb73cc147d0ce57483"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results ...",
              "snippet": "IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update. ... the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592305+00:00",
              "published_date": null,
              "source_hash": "2e91e87aedca4637d9958db22ae54536"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "IDEAYA Precision Oncology Drug Discovery Platform & IND Engine. 7. AI/ML & Structure Based Drug Design to Deliver First-in-Class Development Candidates. Structural Biology & Structure Based Drug Design . Full suite of capabilities . in structural biology, biophysics, & computational chemistry. Ligand bound co-crystal structures . resolved to",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:51.592314+00:00",
              "published_date": null,
              "source_hash": "0d17f183e08bbb01d420c359fe8c2375"
            },
            {
              "url": "",
              "title": "Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know",
              "snippet": "IDEAYA Biosciences, Inc. (IDYA) closed the last trading session ... and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:54.125544+00:00",
              "published_date": "2024-11-08T05:55:00+00:00",
              "source_hash": "f69c878c797bc6f092ed378699e181be"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma",
              "snippet": "This includes an upfront fee of $75 million, potential payments of up to $200 million related to development and regulatory milestones ... for the fiscal year ending December 31, 2024. IDEAYA Biosciences, Inc, a synthetic lethality-focused precision ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:54.125622+00:00",
              "published_date": "2025-01-01T07:13:00+00:00",
              "source_hash": "7ffdc2fb31718347562b780df4627343"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences inks license agreement with Hengrui Pharma for SHR-4849, a novel DLL3 Topo-I-payload ADC targeting SCLC and NET solid tumours",
              "snippet": "IDEAYA Biosciences, Inc., a precision medicine oncology company committed to ... including tumour regression as a monotherapy in multiple models. This drug is currently being evaluated in a phase 1 clinical trial for advanced solid tumours in China ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "retrieved_at": "2025-01-06T21:19:54.125654+00:00",
              "published_date": "2024-12-30T16:01:00+00:00",
              "source_hash": "696794ba535d4aa77cfd8ce3430e1747"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences",
              "snippet": "IDEAYA is a clinical-stage precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638504+00:00",
              "published_date": null,
              "source_hash": "3ab1b433897d93997112882c4376210e"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical ...",
              "snippet": "IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that it has dosed its first ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638607+00:00",
              "published_date": null,
              "source_hash": "e93830419fd7a8e123a08c9441843a24"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. (IDYA) - Yahoo Finance",
              "snippet": "See the company profile for IDEAYA Biosciences, Inc. (IDYA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638622+00:00",
              "published_date": null,
              "source_hash": "124a67277b44e890341906e9cf5884fd"
            },
            {
              "url": "",
              "title": " IDEAYA Biosciences",
              "snippet": "IDEAYA Biosciences, Inc. (the \"Company\") and involve knownand unknown risks, uncertainties and other factorsthat may cause the actual results, levels of activity,performance or achievementsof the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638633+00:00",
              "published_date": null,
              "source_hash": "a8eb5cbaa704d0c7e9fa4d9ef95721eb"
            },
            {
              "url": "",
              "title": " IDEAYA Biosciences",
              "snippet": "or the future financial performance of IDEAYA Biosciences, Inc. (the \"Company\") and involve known and unknown risks, uncertainties and other factors ... - Daro/Crizo MUM Registrational Trial Initiation Q1 2023 IDE397 (MAT2A) -Phase 1/2 . ... medicine therapies with patient biomarkers, including MTAP-deletion (~15% of solid tumors), BRCA ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638643+00:00",
              "published_date": null,
              "source_hash": "2b7e359f103f3a4643e443b66f90d70f"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Inc, IDYA:NSQ summary - FT.com - Financial Times",
              "snippet": "IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead produc t candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638653+00:00",
              "published_date": null,
              "source_hash": "da76d45a3191d872b05fd6e872e96005"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Inc, IDYA:NSQ profile - FT.com - Financial Times",
              "snippet": "IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase).",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638663+00:00",
              "published_date": null,
              "source_hash": "03543184a2c1d1832790df1fd039585e"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences, Inc. (IDYA) Company Profile & Overview - Stock Analysis",
              "snippet": "The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638673+00:00",
              "published_date": null,
              "source_hash": "f1232cf473a84d857463fa4845e8716c"
            },
            {
              "url": "",
              "title": "Ideaya Biosciences | IDYA Stock Price, Company Overview & News - Forbes",
              "snippet": "IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638682+00:00",
              "published_date": null,
              "source_hash": "981f29712cd3a08f3e48bf0c1635c84e"
            },
            {
              "url": "",
              "title": " IDEAYA Biosciences",
              "snippet": "or the future financial performance of IDEAYA Biosciences, Inc. (the \"Company\") and involve known and unknown risks, uncertainties and other factors ... Pursuant to Pfizer Clinical Trial Collaboration and Supply Agreement for MEK and cMETCombinations; IDEAYA retains all IDE196 Commercial Rights ... Patient Impact: Potential First-in-Class ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:19:57.638691+00:00",
              "published_date": null,
              "source_hash": "e806dc19bfa4f2bcfb02cc05f2d244aa"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors",
              "snippet": "Ideaya Biosciences ($IDYA) has taken investors on quite a ride this year. After the stock reached all-time highs in February, it has given it all",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:20:00.093684+00:00",
              "published_date": "2024-12-29T16:18:04+00:00",
              "source_hash": "d60883f08796a5833adc1926997f32b8"
            },
            {
              "url": "",
              "title": "IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma",
              "snippet": "IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected ... inhibitor that is in Phase 1 clinical trial to treat tumors with homologous ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:20:00.093769+00:00",
              "published_date": "2025-01-01T07:13:00+00:00",
              "source_hash": "ea8e137ac9f8b14b44b6eab1c856e95b"
            },
            {
              "url": "",
              "title": "Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3",
              "snippet": "In a deal worth up to $1 billion, Ideaya Biosciences Inc. is in-licensing Jiangsu Hengrui Pharmaceuticals Co. Ltd.'s SHR-4849, a phase I DLL3-targeting opo-I-payload antibody-drug conjugate (ADC). Under terms of the deal,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:20:00.093784+00:00",
              "published_date": "2024-12-30T23:05:00+00:00",
              "source_hash": "7e1e539cb3ef74c552040adcdb3d779e"
            },
            {
              "url": "",
              "title": "BeiGene, Brii and Ideaya ring in 2025 with deal news, betting billions in biobucks on prospects",
              "snippet": "Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences ... which is called SHR-4849, in a phase 1 trial in China. Ideaya plans to file to test the drug candidate in humans in the U.S ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:20:00.093794+00:00",
              "published_date": "2025-01-02T08:30:00+00:00",
              "source_hash": "b6ddc246fafdb0f6e06e2e4b6069a67f"
            },
            {
              "url": "",
              "title": "Ideaya Biosciences doses first patient in IDE161, Keytruda combination trial",
              "snippet": "Ideaya Biosciences (IDYA) announced that it has dosed the first patient in the Ideaya-sponsored Phase 1 trial evaluating the combination of IDE161, the company's investigational small molecule ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "IDEAYA Biosciences Inc. IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "retrieved_at": "2025-01-06T21:20:00.093803+00:00",
              "published_date": "2024-12-10T11:15:00+00:00",
              "source_hash": "204ffa6959d9026408d0586636d29431"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "IDEAYA Biosciences Inc. clinical trial failures or delays",
              "rationale": "Investigate potential risks related to clinical trial outcomes, which could impact regulatory approval and financial stability",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "IDEAYA Biosciences Inc. regulatory challenges or FDA warnings",
              "rationale": "Assess any regulatory hurdles or compliance issues that could delay drug approvals or lead to legal complications",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "IDEAYA Biosciences Inc. controversies in patient recruitment or trial ethics",
              "rationale": "Examine potential ethical concerns in clinical trial practices, such as patient recruitment or informed consent, which could harm the company's reputation",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:20:15.102997",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}